Cencora, Inc. (NYSE:COR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Cencora, Inc. (NYSE:COR) have been given an average rating of “Moderate Buy” by the thirteen brokerages that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $399.00.

A number of analysts have commented on COR shares. JPMorgan Chase & Co. upped their price target on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Robert W. Baird set a $415.00 price objective on Cencora in a research note on Tuesday, January 13th. Wells Fargo & Company upped their target price on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Finally, Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 15,220 shares of company stock valued at $5,282,867 in the last quarter. 0.38% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently made changes to their positions in COR. Mirae Asset Global Investments Co. Ltd. grew its holdings in Cencora by 13.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock worth $15,086,000 after acquiring an additional 5,543 shares during the last quarter. AustralianSuper Pty Ltd bought a new position in shares of Cencora during the third quarter valued at about $26,191,000. Mediolanum International Funds Ltd boosted its holdings in shares of Cencora by 133.0% during the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after purchasing an additional 32,138 shares during the period. Advisors Asset Management Inc. boosted its holdings in shares of Cencora by 40.3% during the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock worth $5,407,000 after purchasing an additional 4,973 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of Cencora by 4.0% in the third quarter. Rhumbline Advisers now owns 430,150 shares of the company’s stock worth $134,435,000 after purchasing an additional 16,539 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $349.69 on Friday. The business has a 50-day moving average of $355.58 and a 200-day moving average of $338.47. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The company has a market capitalization of $68.03 billion, a price-to-earnings ratio of 42.03, a price-to-earnings-growth ratio of 1.63 and a beta of 0.68. Cencora has a 1 year low of $252.49 and a 1 year high of $377.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same period in the prior year, the business posted $3.73 earnings per share. The firm’s revenue was up 5.5% on a year-over-year basis. As a group, equities research analysts anticipate that Cencora will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s dividend payout ratio is presently 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.